Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress

Autolus Therapeutics (AUTL) announced updated long-term data from its FELIX study of obecabtagene autoleucel (obe-cel) in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). After a median follow-up of 42.6 months, the median duration of response was reported, with over half of patients remaining in remission at 24 months and 38% of ongoing responders not requiring subsequent therapy by month 33, suggesting that obe-cel may be a definitive treatment for a subset of r/r B-ALL patients. The data also indicated that obe-cel is effective regardless of patient age, with a favorable benefit and risk profile.

Analysis

Autolus Therapeutics (AUTL) has presented significant updated long-term data from the FELIX study for obecabtagene autoleucel (obe-cel) in adult relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), reinforcing its therapeutic potential as an FDA and MHRA approved product. The study now reports a median duration of response of 42.6 months, with further detailed analysis at a median follow-up of 32.8 months showing that 38.4% of responders maintained ongoing remission without consolidative stem cell transplant or other subsequent therapies. This finding, coupled with over half of patients remaining in remission at 24 months, a 24-month Event Free Survival rate of 43%, and an Overall Survival rate of 46% exhibiting an emerging long-term plateau, strongly suggests obe-cel could serve as a definitive treatment for a considerable subset of these high-risk patients. Critically, the extended follow-up revealed no new safety signals or Grade ≥3 secondary malignancies, and obe-cel demonstrated consistent efficacy and a positive benefit-risk profile across different age groups, including older adults (≥55 years). The associated "strongly positive" sentiment (0.85) and significant market impact score (0.7) underscore the clinical importance of these results, which also identify factors like earlier obe-cel use and lower disease burden at lymphodepletion as correlates for improved remission rates and long-term outcomes, guiding future clinical application.

Key Decisions for Investors

• Investors should consider the enhanced commercial prospects for obe-cel, an already approved therapy, given the compelling long-term efficacy, including a median duration of response of 42.6 months and 38.4% of responders remaining in remission without further therapy, which supports its potential as a definitive treatment in r/r B-ALL.
• The consistent safety profile with no new signals and demonstrated efficacy across diverse age groups, reflected in the 'strongly positive' sentiment, may warrant a re-evaluation of Autolus's market penetration potential and long-term growth trajectory for AUTL.
• Monitoring Autolus's progress in leveraging identified predictive factors for remission, such as earlier obe-cel use and lower disease burden, and advancements in managing hematotoxicity, will be crucial as these could further solidify obe-cel's clinical and commercial differentiation.